What is the Origin of CJC Ipamorelin?

Both peptides are synthetic compounds developed through advancements in peptide chemistry and endocrinology to selectively target the pituitary gland's somatotroph cells. CJC-1295 was engineered for a prolonged half-life, while Ipamorelin offers selective GH release without significantly elevating prolactin or cortisol. This combination reflects a precision approach to hormonal optimization with reduced side effects.

What is the Mechanism of CJC Ipamorelin?

CJC-1295 binds to the GHRH receptor on the pituitary, acting as a long-lasting secretagogue to amplify the natural growth hormone pulse amplitude. Ipamorelin, a ghrelin mimetic, binds to the ghrelin receptor (GHSR-1a), which further enhances the release of growth hormone from the pituitary. The combined action provides a sustained and robust pulsatile stimulation, maximizing the physiological release of growth hormone without the blunt pharmacological effect of exogenous GH administration.

CJC Ipamorelin

Meaning

CJC Ipamorelin is a combination peptide therapy comprising two distinct Growth Hormone Releasing Hormones (GHRH) analogues, CJC-1295 (a GHRH analog with Drug Affinity Complex) and Ipamorelin (a Growth Hormone Releasing Peptide or GHRP). This synergistic blend is specifically designed to stimulate the pituitary gland to release endogenous growth hormone in a pulsatile, more physiological manner. It is used clinically to enhance tissue repair, improve body composition, and support overall vitality.